PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Alex Jan van der Eb et al.

Serial No.: 08/973,560

Filed: December 5, 1997

For: p-53 BINDNG PROTEIN CALLED MDMX AND ENCODING SEQUENCES FOR SAID PROTEIN

Examiner: To be assigned

Group Art Unit: To be assigned

Attorney Docket No.: 3839US

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the document listed on attached Form PTO-1449 be considered by the Examiner and made of record. A Copy of the listed document is enclosed pursuant to 37 C.F.R. § 1.98(a).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability

as defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56(b) exists.

<div align="center">Foreign Patent Documents</div>

Document No.	Date	Country
WO 97/00326	January 3, 1997	PCT

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56 & 1.175, applicant hereby identifies the following listed copending applications naming the same inventors:

Serial No.: 08/793,170
Filed: March 25, 1997
For: PACKAGING SYSTEMS FOR HUMAN RECOMBINANT ADENOVIRUS
TO BE USED IN GENE THERAPY

Serial No.: 09/333,820
Filed: June 15, 1999
For: PACKAGING SYSTEMS FOR HUMAN RECOMBINANT ADENOVIRUS
TO BE USED IN GENE THERAPY

Serial No.: 09/334,765
Filed: June 16, 1999
For: PACKAGING SYSTEMS FOR HUMAN RECOMBINANT ADENOVIRUS
TO BE USED IN GENE THERAPY

Serial No.: 09/298,745
Filed: April 23, 1999
For: MEANS AND METHODS FOR NUCLEIC ACID DELIVERY VEHICLE
DESIGN AND NUCLEIC ACID TRANSFER

Applicants offer to supply any explanation or discussion of the documents which the Examiner feels is necessary or desirable and which is requested.

This Information Disclosure Statement is believed to be filed before the mailing date of the first Office Action on the merits in the above-identified application.

Respectfully submitted,

Allen C. Turner
Registration No. 33,041
Attorney for Applicants
TRASK, BRITT & ROSSA
P. O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: (801) 532-1922

Date: July 26, 1999

ACT/df
Enclosures: Form PTO-1449
Copy of documents cited

Form PTO-1449			Docket Number (Optional) 3839US	Application Number 08/973,560
INFORMATION DISCLOSURE CITATION IN AN APPLICATION *(Use several sheets if necessary)*			Applicant **van der Eb, et al**	
			Filing Date **December 5, 1997**	Group Art Unit **To be assigned**

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation YES	Translation NO
	WO 97/00326	01/03/97	PCT				

OTHER DOCUMENTS   (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.